ELIGANT: a Phase 4, interventional, safety study of leuprorelin acetate (ELIGARD®) in Asian men with prostate cancer.
Transl Androl Urol
; 11(2): 179-189, 2022 Feb.
Article
in En
| MEDLINE
| ID: mdl-35280654
Full text:
1
Collection:
01-internacional
Database:
MEDLINE
Type of study:
Clinical_trials
Aspects:
Patient_preference
Language:
En
Journal:
Transl Androl Urol
Year:
2022
Document type:
Article
Affiliation country:
Malaysia
Country of publication:
China